Determinants of Warfarin Metabolism
NCT00162474 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1000
Last updated 2026-04-21
Summary
The anticoagulant effect of warfarin varies greatly among individuals. Some of this variability is attributed to differences in the activity of CYP2C9, the predominant enzyme involved in the metabolism of S-warfarin.
The present study is designed to define the differences in warfarin metabolism among healthy individuals carrying different CYP2C9 genotypes. In addition, the study will define the correlation between the phenytoin metabolic ratio, a marker of CYP2C9 activity in vivo, and warfarin metabolism.
Conditions
- Healthy
Interventions
- DRUG
-
Warfarin
Each participant may be given at least one CYP2C9 substrate from the following list: Warfarin, Phenytoin, Losartan, Flurbiprofen and Siponimod.
- DRUG
-
Phenytoin
Each participant may be given at least one CYP2C9 substrate from the following list: Warfarin, Phenytoin, Losartan, Flurbiprofen and Siponimod.
- DRUG
-
Losartan & Hydrochlorothiazide
Each participant may be given at least one CYP2C9 substrate from the following list: Warfarin, Phenytoin, Losartan, Flurbiprofen and Siponimod.
- DRUG
-
Flurbiprofen
Each participant may be given at least one CYP2C9 substrate from the following list: Warfarin, Phenytoin, Losartan, Flurbiprofen and Siponimod.
- DRUG
-
Siponimod
Each participant may be given at least one CYP2C9 substrate from the following list: Warfarin, Phenytoin, Losartan, Flurbiprofen and Siponimod.
- DRUG
-
Dicloxacillin
To explore possible effect of dicloxacillin on CYP2C9 activity, some participants will be administered single dose of warfarin and phenytoin before and after intake of dicloxacillin.
Sponsors & Collaborators
-
Hadassah Medical Organization
lead OTHER
Principal Investigators
-
Yoseph Caraco, MD · Hadassah Medical Organization
Study Design
- Allocation
- NA
- Purpose
- OTHER
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 20 Years
- Max Age
- 50 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2003-09-30
- Primary Completion
- 2030-12-31
- Completion
- 2030-12-31
Countries
- Israel
Study Locations
More Related Trials
-
Prospective Genotyping For Total Hip or Knee Replacement Patients Receiving Warfarin (Coumadin)
NCT00634907 ·Status: COMPLETED ·Phase: NA
-
Improving Anticoagulant Therapy Through Warfarin Metabolite Profiling
NCT01964794 ·Status: COMPLETED
-
Pharmacogenetics of Warfarin in Puerto Ricans.
NCT01318057 ·Status: COMPLETED
-
Predictors of Anticoagulation Control on Warfarin Therapy
NCT00905177 ·Status: COMPLETED
-
Pharmacogenetics of Warfarin Induction and Inhibition
NCT01447511 ·Status: COMPLETED ·Phase: NA
-
Study of Genetic Factors Other Than CYP2C9 and VKORC1 That Influence Warfarin Dose Requirements in a South-east Asian Population
NCT01050920 ·Status: UNKNOWN
-
Safer Warfarin Treatment
NCT01042067 ·Status: SUSPENDED
-
Pharmacogenetic Dosing of Warfarin
NCT02065388 ·Status: COMPLETED ·Phase: PHASE3
-
VKORC1 and CYP2C9 Gene Polymorphisms and Warfarin Management
NCT00970892 ·Status: UNKNOWN
-
Genotype-Guided Warfarin Therapy Trial
NCT00904293 ·Status: COMPLETED ·Phase: NA
-
A Pharmacogenetic Study of Warfarin Dosing, "The COUMA-GEN Study"
NCT00334464 ·Status: COMPLETED ·Phase: NA
-
Clarification of Optimal Anticoagulation Through Genetics
NCT00839657 ·Status: COMPLETED ·Phase: PHASE3
-
Applying Pharmacogenetic Algorithms to Individualize Dosing of Warfarin
NCT00927862 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Association Between Genetic Variant Scores and Warfarin Effect
NCT03894878 ·Status: COMPLETED
-
Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)
NCT01305148 ·Status: SUSPENDED ·Phase: NA
-
Comparison of Warfarin Dosing Using Decision Model Versus Pharmacogenetic Algorithm
NCT00511173 ·Status: COMPLETED ·Phase: PHASE4
-
Clinical and Economic Implications of Genetic Testing for Warfarin Management
NCT00964353 ·Status: COMPLETED ·Phase: PHASE4
-
A Genomic Approach to Warfarin Dose Prescription in Admixed Caribbean Hispanics
NCT02345356 ·Status: COMPLETED
-
The Clinical and Economic Impact of Pharmacogenomic Testing of Warfarin Therapy in Typical Community Practice Settings
NCT00830570 ·Status: COMPLETED
-
PRospective Evaluation Comparing Initiation of Warfarin StrategiEs (PRECISE): Pharmacogenetic-guided Versus Usual Care
NCT00377143 ·Status: WITHDRAWN ·Phase: PHASE4
-
Warfarin - How Good Are we at Maintaining Target Range ?
NCT01081327 ·Status: COMPLETED
-
Applying Pharmacogenetics to Warfarin Dosing in Chinese Patients
NCT01610141 ·Status: UNKNOWN ·Phase: PHASE4
-
Duloxetine - Warfarin Pharmacodynamic Study
NCT00533026 ·Status: COMPLETED ·Phase: PHASE1
-
Assessment of 2012 Bioequivalence Standards for Warfarin
NCT02574754 ·Status: COMPLETED ·Phase: PHASE1
-
EUropean Pharmacogenetics of AntiCoagulant Therapy - Phenprocoumon
NCT01119274 ·Status: COMPLETED ·Phase: PHASE4